Some 845 plaintiffs in the federal Levaquin multidistrict litigation have
reached settlements with manufacturer Johnson & Johnson over alleged
personal injury claims, according to an Oct. 30 filing in the proceedings (Levaquin Products Liability
Litigation, In re, D. Minn., No. 08-1943, status report filed
Plaintiffs sued Johnson & Johnson and subsidiary Ortho-McNeil Janssen
Pharmaceuticals Inc., alleging the antibiotic causes tendon rupture. Federal
suits were consolidated in the U.S. District Court for the District of Minnesota
Settlement is proceeding in several groups, an Oct. 30 status conference
report said. The first group involves about 845 plaintiffs, represented by a
small number of firms, who reached a settlement in September. The plaintiffs
anticipate the agreement will be finalized in the next two weeks, the report
The second settlement group involves about 130 plaintiffs, represented by
other firms, who are interested in participating in the settlement reached by
the first group.
A third group involves plaintiffs represented by counsel who have a small
number of cases in the MDL. This group also includes plaintiffs who are not
working through MDL counsel, but have reached out directly to defendants to
discuss settlement options. Some 60 plaintiffs are involved in the third group,
the report said.
The terms of the settlements are confidential, plaintiffs' attorney Ronald
Goldser of Zimmerman Reed told BNA Nov. 6.
The parties also are working toward developing a standardized settlement
protocol, the report said.
There are 1,793 cases in the federal MDL, according to a Sept. 5 statistics
report. The status conference report is at http://op.bna.com/pslr.nsf/r?Open=jstg-8znpc3.